アブストラクト
Japanese
| Title | 全身型重症筋無力症に対する補体をターゲットとした分子標的薬 ; C5阻害薬 |
|---|---|
| Subtitle | 第40回日本神経治療学会学術集会特集1 シンポジウム4 : 重症筋無力症の新たな治療戦略-3 |
| Authors | 増田眞之** |
| Authors (kana) | |
| Organization | **東京医科大学神経学分野脳神経内科 |
| Journal | 神経治療学 |
| Volume | 40 |
| Number | 3 |
| Page | 298-300 |
| Year/Month | 2023 / |
| Article | 報告 |
| Publisher | 日本神経治療学会 |
| Abstract | 「はじめに」重症筋無力症/ランバート・イートン筋無力症候群診療ガイドライン2022では, MG患者に十分なquality of life(QOL)が担保される早期MM-5mg(経口prednisolone(PSL)5mg/日以下でminimal manifestations(MM)レベル)の達成を目標に, 漸増・漸減法による高用量経口ステロイド療法を推奨せず, 経口PSL10mg/日以下とし, 非経口の速効性治療(fast-acting treatment: FT, 免疫グロブリン静注療法, 血漿浄化療法, 高用量メチルPSL静脈内投与, あるいはこれらを組み合わせた治療)を初期治療や症状悪化時に積極的に行い, 早期改善と経口PSL量抑制の両立を図ることを推奨している. しかし, このようなアプローチを積極的に繰り返し行っても6か月以上MM-5mgに達しているMG患者は65%程度に留まっている. 新ガイドラインではFTを繰り返し行ってもMM-5mgを達成出来ない患者群を新たに難治性MGと明記された. さらに難治性アセチルコリンレセプター抗体(AChRAb)陽性全身型MG(gMG)の治療アルゴリズムとして, 分子標的治療薬のeculizumabが記載された点は画期的である. |
| Practice | 臨床医学：内科系 |
| Keywords | myasthenia gravis, C5, eculizumab, ravulizumab, zilucoplan |
English
| Title | Complement-targeted molecular agents for generalized myasthenia gravis ; C5 inhibitors |
|---|---|
| Subtitle | |
| Authors | Masayuki MASUDA |
| Authors (kana) | |
| Organization | Tokyo Medical University Department of Neurology |
| Journal | Neurological Therapeutics |
| Volume | 40 |
| Number | 3 |
| Page | 298-300 |
| Year/Month | 2023 / |
| Article | Report |
| Publisher | Japanese Society of Neurological Therapeutics |
| Abstract | The Myasthenia Gravis (MG) Clinical Practice Guideline 2014 set a treatment goal of "MM-or-better-5mg" and indicated an "Early fast-acting treatment strategy." In May of 2022, the MG/Lambert-Eaton Myasthenia Syndrome Clinical Practice Guideline 2022 was published and included the complement C5 inhibitor Eculizumab and newly clarifies the definition of refractory. In Japan, a new complement C5 inhibitor, Ravulizumab, has been approved and clinical trials of Zilcoplan are underway. In the future, it is expected to further improve the QOL of patients. |
| Practice | Clinical internal medicine |
| Keywords | myasthenia gravis, C5, eculizumab, ravulizumab, zilucoplan |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) 日本神経学会 : 重症筋無力症/ランバート・イートン筋無力症候群診療ガイドライン2022. 南江堂 : 2022
- 2) Masuda M, Utsugisawa K, Suzuki S et al : The MG-QOL15 Japanese version : validation and associations with clinical factors. Muscle Nerve 46 : 166-173, 2012
- 3) Nagane Y, Suzuki S, Suzuki N et al : Early aggressive treat-ment strategy against myasthenia gravis. Eur Neurol 65 : 16-22, 2011
- 4) Suzuki S, Masuda M, Uzawa A et al : Japan MG registry : Chronological surveys over 10 years. Clin Exp Neuroimmu-nol 1-8, 2022. doi : 10.1111/cen3. 12731
- 5) Murai H : Japanese clinical guidelines for myasthenia gravis : Putting into practice. Clin Exp Neuroimmunol 6 : 21-31, 2015
残りの17件を表示する
- 6) Albazli K, Kaminski HJ, Howard JF Jr : Complement Inhibi-tor Therapy for Myasthenia Gravis. Front Immunol 11 : 917, 2020
- 7) Nakano S, Engel AG : Quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology 3 : 1167-1172, 1993
- 8) Thomas TC, Rollins SA, Rother RP et al : Inhibition of com-plement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 33 : 1389-1401, 1996
- 9) Howard JF Jr, Utsugisawa K, Benatar M et al : Safety and efficacy of eculizumab in anti-acetylcholine receptor anti-body-positive refractory generalised myasthenia gravis(RE-GAIN): a phase 3, randomised, double-blind, placebo-con-trolled, multicentre study. Lancet Neurol 16 : 976-986, 2017
- 10) Murai H, Suzuki S, Hasebe M et al : Safety and effectiveness of eculizumab in Japanese patients with generalized myas-thenia gravis : interim analysis of post-marketing surveil-lance. Ther Adv Neurol Disord 14 : 17562864211001995, 2021
- 11) Murai H, Suzuki S, Fukamizu Y et al : Safety and effective-ness of eculizumab in Japanese patients with generalized myasthenia gravis : Analysis of 1-year postmarketing sur-veillance. Clin Exp Neuroimmunol 13 : 280-289, 2022
- 12) Acevedo R, Bai X, Borrow R et al : The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide : Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Ex-pert Rev Vaccines 18 : 15-30, 2019
- 13) Oyama M, Okada K, Masuda M et al : Suitable indications of eculizumab for patients with refractory generalized myasthe-nia gravis. Ther Adv Neurol Disord 13 : 1-9, 2020
- 14) Kulasekararaj AG, Hill A, Rottinghaus ST et al : Ravulizu-mab(ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH : the 302 study. Blood 133 : 540-549, 2019
- 15) Barbour T, Scully M, Ariceta G et al : Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Ure-mic Syndrome in Adults. Kidney Int Rep 6 : 1603-1613, 2021
- 16) Vu T, Meisel A, Mantegazza R et al : Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. NEJM Evid 1, 2022
- 17) Howard JF Jr, Vissing J, Gihus NE et al : Zilucoplan : An In-vestigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis. Expert Opin Investig Drugs 30 : 483-493, 2021
- 18) Vu T, Genge A, Hussain Y et al : Efficacy and safety of ziluco-plan in myasthenia gravis : Responder analysis from the randomized Phase 3 RAISE trial. Poster 200, AANEM 2022
- 19) Howard JF Jr, Karam C, Yountz M et al : Long-term efficacy of eculizumab in refractory generalized myasthenia gravis : responder analyses. Ann Clin Transl Neurol 8 : 1398-1407, 2021
- 20) Nishimura J, Yamamoto M, Hayashi S et al : Genetic var-iants in C5 and poor response to eculizumab. N Engl J Med 370 : 632-639, 2014
- 21) Obaid AH, Zografou C, Vadysirisack DD et al : Heterogeneity of Acetylcholine Receptor Autoantibody-Mediated Comple-ment Activity in Patients With Myasthenia Gravis. Neurol Neuroimmunol Neuroinflamm 9 : e1169, 2022
- 22) Rose N, Holdermann S, Callegari I et al : Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities. Acta Neuropathol 144 : 1005-1025, 2022
